Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

1 Apr 2008

Abstract excerpt

The c-Met receptor tyrosine kinase has been implicated in cellular transformation induced by mutant Ras, a commonly activated proto-oncogene in non-small cell lung cancer (NSCLC). However, the role of c-Met has not been defined in K-ras-mutant NSCLC, a disease for which no effective targeted therapeutic options currently exist. To acquire a greater understanding of its role, we used genetic and pharmacologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver physiology and pathology
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18413809
DOI: 10.1158/1535-7163.mct-07-2045

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-rasPMID 18413809Read ↗

WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.Semantic proximity Read ↗

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.Semantic proximity Read ↗

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.Semantic proximity Read ↗

Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer.Semantic proximity Read ↗

MET as a possible target for non-small-cell lung cancer.Semantic proximity Read ↗

Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.Semantic proximity Read ↗

Role of c-Met in cancer: emphasis on lung cancer.Semantic proximity Read ↗

Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.Semantic proximity Read ↗

Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.Semantic proximity Read ↗

Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.Semantic proximity Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.